Transgene

Transgene Non-Current Assets

The Non-Current Assets of Transgene (TNG.PA) as of Nov 18, 2026 is 838,000.00 EUR. In the previous year, Non-Current Assets was 9.25 M EUR — a change of -90.94% (lower).

Non-Current Assets

838,000.00EUR

YoY

-90.94%

Last updated:

Non-Current Assets of Transgene is 2024 838,000.00 EUR. Non-Current Assets of Transgene was 2023 9.25 M EUR. It decreases by -90.94% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Non-Current Assets of Transgene is 838,000.00 EUR in 2024.

Non-Current Assets of Transgene changed from 9.25 M EUR to 838,000.00 EUR, representing a -90.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Non-Current Assets Transgene since 2006 – with annual values, charts, and detailed analysis.

Non-current assets are long-term resources not expected to be converted to cash within one year, including property, equipment, and long-term investments.

Non-Current Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Non-Current Assets's Transgene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Transgene

All Key Metrics — Transgene